EU considers booster doses of J&J's COVID-19 vaccine

The European Medicines Agency says it is evaluating whether to authorize booster doses of Johnson & Johnson’s single-shot COVID-19 vaccine

Via AP news wire
Monday 22 November 2021 14:04

The European Medicines Agency says it is evaluating whether to authorize booster doses of Johnson & Johnson's single-shot COVID-19 vaccine.

In a statement Monday, the EU drug regulator said it was considering an application from J&J to recommend booster doses of the J&J vaccine for adults 18 and over, at least two months after they were first immunized. Amid an explosive surge of new coronavirus infections across Europe the EMA said it expected to make a decision on this within weeks.

The U.S. Food and Drug Administration gave the green light to J&J booster doses in October, both for people who initially received the J&J and vaccine and for people who got immunized with other vaccines.

J&J earlier presented results from a large study that found giving a second dose just two months after the first bumped protection against symptomatic COVID-19 to 94% from 70% in U.S. recipients. Giving that booster six months later instead prompted an even bigger jump in virus-fighting antibodies.

EU countries initially ordered about 200 million doses of J&J's vaccine, but only a fraction have been delivered after the company has faced repeated production problems.

The EMA has previously said its 27 nations could consider administering booster doses of vaccines made by Pfizer-BioNTech and Moderna for people who had received the two-dose regimens at least six months before, noting that a third shot would provide additional antibodies against COVID-19. The agency is expected to decide later this week on COVID-19 vaccines for children aged 5 to 11.

___

Read full AP coverage of the pandemic at: https://apnews.com/hub/coronavirus-pandemic

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in